Acquisition of CANGRELOR IV 50MG PO SOL INJ (AUE 202505128) from Lab. Ferrer for ULSASI for the year 2026

This tender involves the procurement of CANGRELOR IV 50MG PO SOL INJ (AUE 202505128) from Lab. Ferrer for the Unidade Local de Saúde do Alto Sávio (ULSASI) for the year 2026. CANGRELOR is an important medication used in various medical treatments, and the tender specifies the need for this specific formulation and dosage. The procurement is aimed at ensuring the availability of this essential drug for healthcare services provided by ULSASI. Interested suppliers must meet the necessary qualifications and adhere to the procurement guidelines set forth by the ULSASI. The tender emphasizes the importance of timely delivery and compliance with quality standards to ensure patient safety and effective treatment outcomes. Suppliers are encouraged to submit their proposals in accordance with the stipulated requirements and deadlines. This acquisition is part of ULSASI's ongoing efforts to maintain a robust supply chain for critical medical supplies, thereby enhancing the quality of healthcare services in the region. The location of the services is within the jurisdiction of ULSASI, which operates in the healthcare sector, focusing on delivering comprehensive medical care to the community.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 3,012.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.